Cargando…

Novel antigens of CAR T cell therapy: New roads; old destination

Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Safarzadeh Kozani, Pooria, Safarzadeh Kozani, Pouya, Rahbarizadeh, Fatemeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065293/ https://www.ncbi.nlm.nih.gov/pubmed/33862524 http://dx.doi.org/10.1016/j.tranon.2021.101079

Ejemplares similares

CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021)

Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
por: Hashem Boroojerdi, Mohadese, et al.
Publicado: (2020)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
por: Nasiri, Fatemeh, et al.
Publicado: (2023)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

AS1411-functionalized delivery nanosystems for targeted cancer therapy
por: Kozani, Pooria Safarzadeh, et al.
Publicado: (2021)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
por: Nasiri, Fatemeh, et al.
Publicado: (2022)

Marine Bacteria versus Microalgae: Who Is the Best for Biotechnological Production of Bioactive Compounds with Antioxidant Properties and Other Biological Applications?
por: Hamidi, Masoud, et al.
Publicado: (2019)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
por: Dabiri, Hamed, et al.
Publicado: (2023)

New cell sources for CAR-based immunotherapy
por: Mazinani, Marzieh, et al.
Publicado: (2023)

CAR-T cell potency: from structural elements to vector backbone components
por: Mazinani, Marzieh, et al.
Publicado: (2022)

New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria
por: Spengler, Gabriella, et al.
Publicado: (2017)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
por: Soltantoyeh, Tahereh, et al.
Publicado: (2021)

Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
por: Rajabzadeh, Alireza, et al.
Publicado: (2021)

Many roads, one destination for T cell progenitors
por: Petrie, Howard T., et al.
Publicado: (2005)

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
por: Zhang, Qingyang, et al.
Publicado: (2020)

Cellular Senescence: Many Roads, One Final Destination
por: Saab, Raya
Publicado: (2010)

COVID-19 diagnostic approaches: different roads to the same destination
por: Kumar, Ramesh, et al.
Publicado: (2020)

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
por: Crowther, Michael D., et al.
Publicado: (2020)

The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
por: Burns, Ian, et al.
Publicado: (2022)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

MLKL post-translational modifications: road signs to infection, inflammation and unknown destinations
por: Liccardi, Gianmaria, et al.
Publicado: (2022)

CAR-T cells: the long and winding road to solid tumors
por: D’Aloia, Maria Michela, et al.
Publicado: (2018)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

CAR T cells for brain tumors: Lessons learned and road ahead
por: Akhavan, David, et al.
Publicado: (2019)

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
por: Taneja, Alankrita, et al.
Publicado: (2021)

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
por: Luksik, Andrew S., et al.
Publicado: (2023)

The old-new car sticker
Publicado: (2000)

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Aparicio, Cristina, et al.
Publicado: (2021)

T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
por: De Bousser, Elien, et al.
Publicado: (2021)

Emerging Novel Combined CAR-T Cell Therapies
por: Nguyen, Anh, et al.
Publicado: (2022)

Road testing new CAR design strategies in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2022)

Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success
por: Michelozzi, Ilaria M., et al.
Publicado: (2021)

Teaching an old dog new tricks: next-generation CAR T cells
por: Tokarew, Nicholas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c1srsqnp6a8a5e6r8e5s7hfaqu